Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Krystal Biotech Inc (KRYS-Q) from The Globe and Mail including charting and trades.

Enrollment spans Europe, the US, and Canada, targeting ~324 GA patients in a randomized, double-masked, sham-controlled phase 2 program. Dosing compares two intravitreal dose levels given every 12 or ...

The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety with preliminary assessments of visual and retinal functional outcomes.

Geographic atrophy management could benefit greatly from the combination of novel therapies and AI-driven imaging technology.

Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and ...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® ...

Ophthalmic research focus grows around glaucoma therapy and device development Webinar spotlight covers BL therapy and ELIOS surgical platform technology Sector discussion expands alongside activity ...

OCU410 targets multiple pathways disrupted in the pathogenesis of dry AMD, such as the complement system, inflammatory cascades, lipid metabolism, and oxidative stress. The current standard-of-care ...